[A case of fulminant hepatitis caused by antiandrogen, flutamide in a patient with prostate cancer].
Luteinizing hormone-releasing hormone analogue, 3.6 mg goserelin acetate and flutamide, 375 mg per day were used to treat metastatic prostate cancer in a 66-year-old male. Marked increase in serum aminotransferases and total bilirubin levels was noted after 7 weeks of treatment. The enzyme levels returned to normal at 2 months following discontinuation of the treatment. Though incidences of severe hepatotoxicity are rare (0.003-0.18%), cases of flutamide-induced death have been reported. Careful monitoring of patients is mandatory while administering flutamide.
Satoh
T
T
Department of Urology, Kitasato University School of Medicine.
Egawa
S
S
Katsuta
M
M
Iwamura
M
M
Uchida
T
T
Koshiba
K
K
D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000556:secondary; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D005485:Flutamide / Q000009:adverse effects*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000726:Androgen Antagonists; D005485:Flutamide